Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Minority Interest (2016 - 2025)

Historic Minority Interest for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $9.0 million.

  • Astrazeneca's Minority Interest rose 100000.0% to $9.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.0 million, marking a year-over-year increase of 100000.0%. This contributed to the annual value of $9.0 million for FY2025, which is 100000.0% up from last year.
  • Per Astrazeneca's latest filing, its Minority Interest stood at $9.0 million for Q4 2025, which was up 100000.0% from $83.0 million recorded in Q3 2025.
  • Astrazeneca's Minority Interest's 5-year high stood at $92.0 million during Q1 2025, with a 5-year trough of -$1.0 million in Q4 2024.
  • Its 5-year average for Minority Interest is $24.2 million, with a median of $5.5 million in 2022.
  • Over the last 5 years, Astrazeneca's Minority Interest had its largest YoY gain of 550000.0% in 2024, and its largest YoY loss of 10434.78% in 2024.
  • Quarter analysis of 5 years shows Astrazeneca's Minority Interest stood at $1.0 million in 2021, then changed by 0.0% to $1.0 million in 2022, then soared by 2200.0% to $23.0 million in 2023, then crashed by 104.35% to -$1.0 million in 2024, then skyrocketed by 1000.0% to $9.0 million in 2025.
  • Its Minority Interest stands at $9.0 million for Q4 2025, versus $83.0 million for Q3 2025 and $7.0 million for Q2 2025.